Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.75) per share and revenue of $1.08 million for the quarter.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $1.18 million during the quarter, compared to analysts' expectations of $1.25 million. On average, analysts expect Celldex Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Celldex Therapeutics Stock Performance
CLDX traded down $0.05 on Friday, reaching $20.66. The company had a trading volume of 598,699 shares, compared to its average volume of 884,988. The stock has a market cap of $1.37 billion, a P/E ratio of -8.04 and a beta of 1.59. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The company's fifty day moving average is $19.09 and its 200 day moving average is $23.17.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a "buy" rating and a $44.00 price target for the company. Morgan Stanley initiated coverage on Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 target price for the company. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, The Goldman Sachs Group cut their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $55.30.
Check Out Our Latest Stock Analysis on Celldex Therapeutics
About Celldex Therapeutics
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Further Reading
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
